Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

Abramowitz, Laurent; Mathieu, N.; Roudot‐Thoraval, Françoise; Lemarchand, Nicolas; Bauër, Pierre; Hennequin, C.; Mitry, Emmanuel; Romelaer, Charlotte; Aparicio, Thomas; Sobhani, Iradj

doi:10.1111/j.1365-2036.2009.04026.x

Cited by 44 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the HAART era, the prognosis in HIV-infected patients with invasive AC improved steadily, becoming similar to that in the uninfected population [24][25][26], except in one study [27] ( Table 2) with 5-year survival rates ranging from 61% to 77%. Additionally, in the U.S., 2-year overall survival (OS) was 77% in HIV-positive patients and 75% in HIV-negative patients [28].…”

Section: Anal Cancermentioning

confidence: 81%

The Evolving Scenario of Non-AIDS-Defining Cancers: Challenges and Opportunities of Care

et al. 2014

View full text Add to dashboard Cite

Background. The impact of highly active antiretroviral therapies (HAART) on the risk of non-AIDS-defining cancers (NADCs) and the role of biological and clinical factors in their pathogenesis are debated issues. The purpose of this review is to examine the epidemiology, etiology, and not-yet-defined pathogenic characteristics of NADCs and discuss topics such as treatment strategies, comorbidity, and multidrug interactions. Four types of NADCs that deserve special attention are examined: anal cancer, Hodgkin lymphoma (HL), hepatocellular carcinoma, and lung cancer. Methods. The PubMed database and the Cochrane Library were searched by focusing on NADCs and on the association among NADCs, HAART, aging, and/or chronic inflammation. All articles were reviewed to identify those reporting variables of interest.

show abstract

Section: Anal Cancermentioning

confidence: 81%

The Evolving Scenario of Non-AIDS-Defining Cancers: Challenges and Opportunities of Care

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Abramowitz et al [60], investigated retrospectively the long-term survival of epidermoid anal cancer in a group of 44 HIV-positive patients and a control group of 107 HIVpatients in the HAART era. After CMT, similar numbers of HIV-positive and HIV-negative patients had grade III-IV toxicity.…”

Section: Study Treatment Schedulementioning

confidence: 99%

Anal Cancer: Focus on HIV-Positive Patients in the HAART Era

Zanet

Berretta

Martellotta

et al. 2011

CHR

View full text Add to dashboard Cite

Anal cancer represents an increasing health problem, especially in immune-compromised patients, as HIV-positive patients. Notably, a significant higher incidence rate is reported among HIV infected patients with the advent of highly active antiretroviral therapy (HAART). To date, no randomised trial supports the correlation between existing screening strategies and reduced progression of anal intraepithelial neoplasia (AIN) to anal cancer or improved survival. Nevertheless, screening and treatment of AIN by topical agents should be implemented in high risk population. Data on invasive anal cancer treatment show that combined modality treatment (CMT) is the treatment of choice. Early reports on HIV-positive patients describe higher treatment toxicity and a relation with lower CD4 count and higher HIV viral load. More recently, reported outcomes seem to be similar in HIV-positive population and general population. Reports on a rise in local recurrence rates and in acute side effects along with a correlation with pre-treatment CD4 counts in HIV-positive patients, are not confirmed by all authors. The development of the first approved vaccine is a milestone in the field of anogenital cancers. However, many questions are still unresolved especially as concerns immunization in the setting of HIV infection.

show abstract

“…In accordance with the World Health Organisation (WHO) tumours of the anal margin are classified as cutaneous tumours. Squamous cell anal carcinomas account for 95% of cancers of the anal canal, with only 5% of these being metastatic at diagnosis [2,3].…”

Section: Epidemiologymentioning

confidence: 99%

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)

Moureau-Zabotto

Vendrely

Abramowitz

et al. 2017

Digestive and Liver Disease

View full text Add to dashboard Cite

show abstract

Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

Abstract: SUMMARY BackgroundPrevious studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.

Cited by 44 publications

References 18 publications

The Evolving Scenario of Non-AIDS-Defining Cancers: Challenges and Opportunities of Care

The Evolving Scenario of Non-AIDS-Defining Cancers: Challenges and Opportunities of Care

Anal Cancer: Focus on HIV-Positive Patients in the HAART Era

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)

Contact Info

Product

Resources

About